Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants. Table 2. Comparison of estimated marginal means of urinary mast cell activation markers between the different visits in patients treated with a six-week course of Bacillus Calmette-Guérin therapy and between the patients diagnosed with NMIBC (Visit 1) and healthy participants.
NMIBC (19) NMIBC (19) NMIBC (19) NMIBC (19) NMIBC (19) NMIBC (19) NMIBC (19) HP (19) HP (19) HP (19)
P value*
P value*
Visit 1 Visit 1 Visit 1 Visit 2 Visit 3 Visit 4 P value+ P value+
N-methylhistamine (nmol/ml) (mean ± SD) N-methylhistamine (nmol/ml) (mean ± SD) 112.09 ± 31.17 112.09 ± 31.17 112.09 ± 31.17 144.59 ± 44.63 118.01 ± 23.15 93.43 ± 25.01 0.001 0.001 71.78 ± 39.39 71.78 ± 39.39 71.78 ± 39.39 71.78 ± 39.39 71.78 ± 39.39 0.005 0.005
Histamine (ng/ml) (mean ± SD) Histamine (ng/ml) (mean ± SD) 32.37 ± 14.16 32.37 ± 14.16 32.37 ± 14.16 54.57 ± 27.45 42.26 ± 27.89 32.79 ± 19.42 0.001 0.001 29.22 ± 17.18 29.22 ± 17.18 29.22 ± 17.18 29.22 ± 17.18 29.22 ± 17.18 0.307 0.307
Tryptase (ng/ml) (mean ± SD) Tryptase (ng/ml) (mean ± SD) 68.11 ± 17.41 68.11 ± 17.41 68.11 ± 17.41 68.71 ± 18.65 42.26 ± 27.89 32.79 ± 19.42 0.206 0.206 68.48 ± 19.66 68.48 ± 19.66 68.48 ± 19.66 68.48 ± 19.66 68.48 ± 19.66 0.816 0.816
SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits). SD = standard deviation; IL= interleukin; TNF-α = tumor necrosis factor alpha; IFN= interferon-gamma; HP = healthy participants; NMIBC = non-muscle invasive bladder cancer. * Mann-U Whitney test (between the patients diagnosed with NMIBC (Visit 1) and healthy participants). + Friedman test (between different visits).